product .• iodoformio usp/nf. ajinomoto •tame polvere ep/usp aspar • aspartame fine granular

Download PRODUCT .• Iodoformio Usp/NF. AJINOMOTO •tame polvere EP/USP Aspar • Aspartame fine granular

Post on 30-Nov-2018

225 views

Category:

Documents

0 download

Embed Size (px)

TRANSCRIPT

  • #FaravelliPharmaDivision

    The Best ingredients for a healthy life

    PRODUCT LIST

    LISTINO PHARMA ok.indd 1 05/09/18 16:20

  • The Best ingredients for a healthy life

    ECCIPIENTI PER OGNI VOSTRA ESIGENZA

    Alcuni esempi:

    uAGENTI FILMANTIuAMIDI E DERIVATIuANTIAGGLOMERANTIuCOLORANTI E PIGMENTIuCONSERVANTIuCORRETTORI DI pHuDILUENTIuDISGREGANTIuDOLCIFICANTI INTENSIVIuLEGANTIuLUBRIFICANTI-GLIDANTIuOPACIZZANTIuPLASTICIZZANTIuPOLIALCOLIuVISCOSIZZANTIuZUCCHERI

    LISTINO PHARMA ok.indd 2 05/09/18 16:20

  • AGRIGUMuGOMMA ARABICA KORDOFAN La gomma arabica una gomma naturale nota anche come gomma acacia, in quanto prodotta da due specie di acacia subsahariana: Acacia senegal ed Acacia seyal. un eccipiente utilizzato soprattutto come stabilizzante o viscosizzante. Spray dried EP/BP/NF Agri Spray Acacia R Agri Spray Acacia MGH

    AJAY GROUPUno dei pi importanti produttori dei derivati dello Iodio.Tutti i prodotti sotto elencati sono utilizzati come intermedi di sintesi chimiche o come fonte di iodio: Acido iodidrico 57% Potassio ioduro USP Rame ioduro Sodio ioduro BP/FU Calcio iodato Potassio iodato Sodio Iodato Iodoformio Usp/NF

    AJINOMOTO Aspartame polvere EP/USPAspartamefinegranularEP/USP Aspartame granulare EP/USPEdulcorante,dolcificanteintensivo

    AKZONOBEL Sodio Idrossido pellets EP/USP pure grade Potassio Idrossido pellets EP/USP pure gradeRegolatoridipH/buffer,intermedidisintesi,reazionidisaponificazioneelavaggi.

    I NOSTRI PARTNER

    #FaravelliPharmaDivision

    LISTINO PHARMA ok.indd 3 05/09/18 16:20

  • I NOSTRI PARTNER

    The Best ingredients for a healthy life

    BUDENHEIM FOSFATI di CALCIO (DI-CAFOS e TRI-CAFOS) diluente Fosfati utilizzati per la produzione di forme solide sia per WG che per DC. Disponibili in varie granulometrie, sono utilizzati anche come principi attivi atipici nella formulazione di prodotti per la cura dellosteoporosi. FOSFATI di SODIO - utilizzati come regolatori di pH o come attivi in prodotti ad azione lassativa. FOSFATO di POTASSIO - utilizzati come apportatori di K FOSFATO di MAGNESIO - utilizzati come apportatori di Mg ORTOFOSFATO di FERRO - utilizzati come apportatori di Fe

    DI-CAFOS A 150Dicalcium phosphate anhydrousCaHPO4

    150 720 840 14 5.06) 23.0

    Elevated surface area Optimized tablet hardness Use with APIs of poor tableting

    properties Superior flowability

    DI-CAFOS A 60Dicalcium phosphate anhydrousCaHPO4

    60 1330 1500 11 7.1 0.25

    Highly increased bulk density Small surface area, minimized

    water adsorption ideal for water-sensitive APIs

    Outstanding flowability

    DI-CAFOS D 160Dicalcium phosphate dihydrate CaHPO4 2 H2O

    160 820 990 17 7.9 0.4 Good compactibility Good tablet hardness Superior flowability

    TRI-CAFOS 500Tricalcium phosphate Ca5(PO4)3OH

    100 500 580 14 6.5 85.0

    Highly enlarged surface area Improved tablet hardness Increases tablet porosity reduction of disintegration times

    Good flowability

    DI-CAFOS A 12Dicalcium phosphate anhydrousCaHPO4

    12 830 1600 48 6.8 1.25 Powder with highly increased

    bulk density Neutral pH

    DI-CAFOS D 14Dicalcium phosphate dihydrate CaHPO4 2 H2O

    14 550 1100 50 7.6 2.5 Powder with lower bulk density

    TRI-CAFOS 250Tricalcium phosphate Ca5(PO4)3OH

    5 250 400 38 7.0 62.0 Low bulk density powder with

    large specific surface area Neutral pH

    TRI-CAFOS 350Tricalcium phosphate Ca5(PO4)3OH

    5 350 750 53 7.0 15.0

    Powder with enhanced bulk density

    Low specific surface area Neutral pH

    TRI-CAFOS 200-7Tricalcium phosphate Ca5(PO4)3OH

    4 200 420 51 7.0 66.0

    Glidant material for multiple use in solid dosage preparations

    Reduced dust formation High bulk density

    M 52-85Dimagnesium phosphate trihydrate MgHPO4 3 H2O

    120 900 1250 20 8.0 0.5 Optimized for use in direct compression

    M 52-83Dimagnesium phosphate trihydrate MgHPO4 3 H2O

    15 500 900 50 8.0 1.7 Powder for granulations and related processes

    Product

    Pharmacopeia Recommended Application

    Special Properties

    USP

    NF

    Ph.E

    ur.

    JP GP2

    )

    Med

    ian

    Part

    icle

    Siz

    e (

    m)1)

    Bulk

    Den

    sity

    (g/l

    )1)

    Tapp

    ed D

    ensi

    ty (g

    /l)1)

    Com

    pres

    sibi

    lity

    Inde

    x (%

    )1)

    pH 10

    % S

    uspe

    nsio

    n1)

    Spec

    ific

    Surfa

    ce A

    rea

    (m2 /

    g)1)

    Dire

    ct C

    ompr

    essi

    on

    Dry

    Gra

    nula

    tion

    Wet

    Gra

    nula

    tion

    Har

    d Ca

    psul

    es

    Soft

    Caps

    ules

    Flow

    Enh

    ance

    men

    t

    pH-R

    egul

    atio

    n &

    Buf

    fer

    Pharma Portfolio for Solid Dosage Forms

    1) All values provided are approximate and not part of the specification 2) GP = German Pharmacopoeia (DAB) 3) Internal test method at 25C 4) powder fineness described according to USP 37 5) not for parenteral applications 6) pH 20% suspension

    Chemische Fabrik Budenheim KG Rheinstrae 27 55257 Budenheim Germany Phone: +49 61 39 - 89 0 pharma@budenheim.com www.budenheim.com

    DI-CAFOS A 150Dicalcium phosphate anhydrousCaHPO4

    150 720 840 14 5.06) 23.0

    Elevated surface area Optimized tablet hardness Use with APIs of poor tableting

    properties Superior flowability

    DI-CAFOS A 60Dicalcium phosphate anhydrousCaHPO4

    60 1330 1500 11 7.1 0.25

    Highly increased bulk density Small surface area, minimized

    water adsorption ideal for water-sensitive APIs

    Outstanding flowability

    DI-CAFOS D 160Dicalcium phosphate dihydrate CaHPO4 2 H2O

    160 820 990 17 7.9 0.4 Good compactibility Good tablet hardness Superior flowability

    TRI-CAFOS 500Tricalcium phosphate Ca5(PO4)3OH

    100 500 580 14 6.5 85.0

    Highly enlarged surface area Improved tablet hardness Increases tablet porosity reduction of disintegration times

    Good flowability

    DI-CAFOS A 12Dicalcium phosphate anhydrousCaHPO4

    12 830 1600 48 6.8 1.25 Powder with highly increased

    bulk density Neutral pH

    DI-CAFOS D 14Dicalcium phosphate dihydrate CaHPO4 2 H2O

    14 550 1100 50 7.6 2.5 Powder with lower bulk density

    TRI-CAFOS 250Tricalcium phosphate Ca5(PO4)3OH

    5 250 400 38 7.0 62.0 Low bulk density powder with

    large specific surface area Neutral pH

    TRI-CAFOS 350Tricalcium phosphate Ca5(PO4)3OH

    5 350 750 53 7.0 15.0

    Powder with enhanced bulk density

    Low specific surface area Neutral pH

    TRI-CAFOS 200-7Tricalcium phosphate Ca5(PO4)3OH

    4 200 420 51 7.0 66.0

    Glidant material for multiple use in solid dosage preparations

    Reduced dust formation High bulk density

    M 52-85Dimagnesium phosphate trihydrate MgHPO4 3 H2O

    120 900 1250 20 8.0 0.5 Optimized for use in direct compression

    M 52-83Dimagnesium phosphate trihydrate MgHPO4 3 H2O

    15 500 900 50 8.0 1.7 Powder for granulations and related processes

    Product

    Pharmacopeia Recommended Application

    Special Properties

    USP

    NF

    Ph.E

    ur.

    JP GP2

    )

    Med

    ian

    Part

    icle

    Siz

    e (

    m)1)

    Bulk

    Den

    sity

    (g/l

    )1)

    Tapp

    ed D

    ensi

    ty (g

    /l)1)

    Com

    pres

    sibi

    lity

    Inde

    x (%

    )1)

    pH 10

    % S

    uspe

    nsio

    n1)

    Spec

    ific

    Surfa

    ce A

    rea

    (m2 /

    g)1)

    Dire

    ct C

    ompr

    essi

    on

    Dry

    Gra

    nula

    tion

    Wet

    Gra

    nula

    tion

    Har

    d Ca

    psul

    es

    Soft

    Caps

    ules

    Flow

    Enh

    ance

    men

    t

    pH-R

    egul

    atio

    n &

    Buf

    fer

    Pharma Portfolio for Solid Dosage Forms

    1) All values provided are approximate and not part of the specification 2) GP = German Pharmacopoeia (DAB) 3) Internal test method at 25C 4) powder fineness described according to USP 37 5) not for parenteral applications 6) pH 20% suspension

    Chemische Fabrik Budenheim KG Rheinstrae 27 55257 Budenheim Germany Phone: +49 61 39 - 89 0 pharma@budenheim.com www.budenheim.com

    LISTINO PHARMA ok.indd 4 05/09/18 16:20

  • I NOSTRI PARTNER

    #FaravelliPharmaDivision

    K 51-12Monopotassium phosphateKH2PO4

    250 1200 1500 20 4.3(5%) 16.2 0.38

    Moderately fine, crystalline powder Shows fair flowability Effective buffering systems in neutral pH

    range with disodium phosphate

    K 52-01Dipotassium phosphateK2HPO4

    5) 150 370 550 33 8.9(5%) 159.0 4.82 Fine powder Hygroscopic material of high solubility

    N 51-13Monosodium phosphate anhydrous NaH2PO4

    150 900 1400 36 4.4(5%) 85.0 2.58 Fine powder but increased dissolution

    rate

    N 51-15Monosodium phosphate anhydrous NaH2PO4

    500 1200 1300 8 4.4(5%) 85.0 0.96 Coarse crystalline material of excellent

    powder flow Slower dissolution rate than N 51-13

    N 51-10Monosodium phosphate monohydrate NaH2PO4 H2O

    650 1200 1300 8 4.4(5%) 97.8 0.91 Coarse crystalline material of excellent

    flowability

    N 51-12Monosodium phosphate dihydrate NaH2PO4 2 H2O

    680 1100 1200 8 4.3(5%) 110.5 2.04

    Coarse crystalline material of excellent flowability

    Faster dissolution rate t